199 related articles for article (PubMed ID: 2157956)
1. Mutational alteration of the breakage/resealing subunit of bacteriophage T4 DNA topoisomerase confers resistance to antitumor agent m-AMSA.
Huff AC; Ward RE; Kreuzer KN
Mol Gen Genet; 1990 Mar; 221(1):27-32. PubMed ID: 2157956
[TBL] [Abstract][Full Text] [Related]
2. Bacteriophage T4 DNA topoisomerase is the target of antitumor agent 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) in T4-infected Escherichia coli.
Huff AC; Leatherwood JK; Kreuzer KN
Proc Natl Acad Sci U S A; 1989 Feb; 86(4):1307-11. PubMed ID: 2537494
[TBL] [Abstract][Full Text] [Related]
3. Evidence for a common mechanism of action for antitumor and antibacterial agents that inhibit type II DNA topoisomerases.
Huff AC; Kreuzer KN
J Biol Chem; 1990 Nov; 265(33):20496-505. PubMed ID: 2173709
[TBL] [Abstract][Full Text] [Related]
4. Mutations of the bacteriophage T4 type II DNA topoisomerase that alter sensitivity to antitumor agent 4'-(9-acridinylamino)methanesulfon-m-anisidide and an antibacterial quinolone.
Freudenreich CH; Chang C; Kreuzer KN
Cancer Res; 1998 Mar; 58(6):1260-7. PubMed ID: 9515814
[TBL] [Abstract][Full Text] [Related]
5. Role of recombinational repair in sensitivity to an antitumour agent that inhibits bacteriophage T4 type II DNA topoisomerase.
Neece SH; Carles-Kinch K; Tomso DJ; Kreuzer KN
Mol Microbiol; 1996 Jun; 20(6):1145-54. PubMed ID: 8809767
[TBL] [Abstract][Full Text] [Related]
6. Mutagenicity of topoisomerase-active agents in bacteriophage T4.
DeMarini DM; Lawrence BK
Teratog Carcinog Mutagen; 1988; 8(5):293-301. PubMed ID: 2905838
[TBL] [Abstract][Full Text] [Related]
7. Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells.
Bakic M; Chan D; Andersson BS; Beran M; Silberman L; Estey E; Ricketts L; Zwelling LA
Biochem Pharmacol; 1987 Dec; 36(23):4067-77. PubMed ID: 2825713
[TBL] [Abstract][Full Text] [Related]
8. Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione S transferase.
Lefevre D; Riou JF; Ahomadegbe JC; Zhou DY; Benard J; Riou G
Biochem Pharmacol; 1991 Jun; 41(12):1967-79. PubMed ID: 1645555
[TBL] [Abstract][Full Text] [Related]
9. Bacteriophage T4 mutants hypersensitive to an antitumor agent that induces topoisomerase-DNA cleavage complexes.
Woodworth DL; Kreuzer KN
Genetics; 1996 Jul; 143(3):1081-90. PubMed ID: 8807283
[TBL] [Abstract][Full Text] [Related]
10. A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
Prost S; Riou G
Biochem Pharmacol; 1994 Aug; 48(5):975-84. PubMed ID: 8093110
[TBL] [Abstract][Full Text] [Related]
11. The interaction between nuclear topoisomerase II activity from human leukemia cells, exogenous DNA, and 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) or 4-(4,6-O-ethylidene-beta-D-glucopyranoside) (VP-16) indicates the sensitivity of the cells to the drugs.
Estey EH; Silberman L; Beran M; Andersson BS; Zwelling LA
Biochem Biophys Res Commun; 1987 Apr; 144(2):787-93. PubMed ID: 3034264
[TBL] [Abstract][Full Text] [Related]
12. A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents.
O'Reilly EK; Kreuzer KN
Biochemistry; 2002 Jun; 41(25):7989-97. PubMed ID: 12069589
[TBL] [Abstract][Full Text] [Related]
13. Repair of topoisomerase-mediated DNA damage in bacteriophage T4.
Stohr BA; Kreuzer KN
Genetics; 2001 May; 158(1):19-28. PubMed ID: 11333215
[TBL] [Abstract][Full Text] [Related]
14. Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus.
Yamashita Y; Kawada S; Fujii N; Nakano H
Biochemistry; 1991 Jun; 30(24):5838-45. PubMed ID: 1646001
[TBL] [Abstract][Full Text] [Related]
15. Bacteriophage T4, a model system for understanding the mechanism of type II topoisomerase inhibitors.
Kreuzer KN
Biochim Biophys Acta; 1998 Oct; 1400(1-3):339-47. PubMed ID: 9748648
[TBL] [Abstract][Full Text] [Related]
16. Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II.
Lee MS; Wang JC; Beran M
J Mol Biol; 1992 Feb; 223(4):837-43. PubMed ID: 1311390
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
[TBL] [Abstract][Full Text] [Related]
18. Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II.
Zwelling LA; Hinds M; Chan D; Mayes J; Sie KL; Parker E; Silberman L; Radcliffe A; Beran M; Blick M
J Biol Chem; 1989 Oct; 264(28):16411-20. PubMed ID: 2550442
[TBL] [Abstract][Full Text] [Related]
19. The production of topoisomerase II-mediated DNA cleavage in human leukemia cells predicts their susceptibility to 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA).
Bakic M; Beran M; Andersson BS; Silberman L; Estey E; Zwelling LA
Biochem Biophys Res Commun; 1986 Jan; 134(2):638-45. PubMed ID: 3004458
[TBL] [Abstract][Full Text] [Related]
20. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
Ling YH; Andersson BS; Nelson JA
Cancer Biochem Biophys; 1990 Jan; 11(1):23-30. PubMed ID: 2159843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
